Activity Description

In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic.

Target Audience

This activity has been designed to meet the educational needs of urologists, oncologists, physician’s assistants, nurse practitioners, and other health care professionals involved in the management of patients with prostate cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the rationale for therapeutic targeting of DNA repair defects and the mechanism of PARP inhibition in managing BRCA-mutant prostate cancer
• Review companion diagnostic tests that detect germline and somatic mutations within the DNA repair pathways
• Discuss the latest evidence with PARP inhibitors in advanced prostate cancer harboring DNA repair defects
• Identify patients with prostate cancer who may be candidates for clinical trial based therapeutic approaches, including studies testing combination regimens with PARP inhibitor components

Providership, Credit, and Support

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, Inc., and Merck & Co., Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Chair
Emmanuel S. Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Emmanuel S. Antonarakis, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Bayer Corporation; Dendreon Pharmaceuticals LLC; Clovis Oncology; Eli Lilly and Company; ESSA Pharma, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Medivation; Merck & Co., Inc.; and sanofi-aventis U.S. LLC.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Dendreon Pharmaceuticals LLC; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and Tokai Pharmaceuticals Inc.
Other Financial or Material Support from Qiagen as a patent holder/licenser.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Christopher Jakubowski, MD

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView